Generation of a new monoclonal antibody against MALT1 by genetic immunization

Hybridoma

Volumn 26, Issue 2, 2007, Pages 86-91

  Maestre, Lorena ^a   Fontan, Lorena ^b   Martinez Climent, Jose Angel ^b   Garcia, Jose Francisco ^a   Cigudosa, Juan Cruz ^a   Roncador, Giovanna ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HELIUM; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DNA VECTOR; GENE GUN; GENE SEQUENCE; GENE TRANSLOCATION; GENETIC CODE; GENETIC IMMUNIZATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; CASPASES; CELL LINE, TUMOR; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; TRANSFECTION;

EUKARYOTA;

EID: 34247632958     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2006.044     Document Type: Article

References (32)

1. Leinonen J, Niemela P, Lovgren J, Bocchi L, Pettersson K, Nevanlinna H, and Stenman UH: Characterization of monoclonal antibodies against prostate specific antigen produced by genetic immunization. J Immunol Meth 2004;289:157-167.
2. Costagliola S, Rodien P, Many MC, Ludgate M, and Vassart G: Genetic immunization against the human thyrotropin receptor causes thyroiditis and allows production of monoclonal antibodies recognizing the native receptor. J Immunol 1998;160:1458-1465.
3. Chambers RS and Johnston SA: High-level generation of polyclonal antibodies by genetic immunization. Nat Biotechnol 2003; 21:1088-1092.
4. Barry MA, Barry ME, and Johnston SA: Production of monoclonal antibodies by genetic immunization. Biotechniques 1994;16: 616-618, 620.
5. Pupa SM, Forti S, Invernizzi AM, Giovanazzi R, Twal WO, Argraves WS, and Menard S: Monoclonal antibody to fibulin-1 generated by genetic immunization. J Cell Biochem 2003;89:647-652.
6. Puttikhunt C, Kasinrerk W, Srisa-ad S, Duangchinda T, Silakate W, Moonsom S, Sittisombut N, and Malasit P: Production of anti-dengue NS1 monoclonal antibodies by DNA immunization. J Virol Meth 2003;109:55-61.
7. Kilpatrick KE, Kerner S, Dixon EP, Hutchins JT, Parham JH, Condreay JP, and Pahel G: In vivo expression of a GST-fusion protein mediates the rapid generation of affinity matured monoclonal antibodies using DNA-based immunizations. Hybrid Hybridomics 2002;21:237-243.
8. Johnston SA and Tang DC: Gene gun transfection of animal cells and genetic immunization. Methods Cell Biol 1994;43(Pt A): 353-365.
9. Garcia JF, Garcia JF, Maestre L, Lucas E, Sanchez-Verde L, Romero-Chala S, Piris MA, and Roncador G: Genetic immunization: a new monoclonal antibody for the detection of BCL-6 protein in paraffin sections. J Histochem Cytochem 2006; 54:31-38.
10. Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK, De Wolf-Peeters C, Hagemeijer A, Van den Berghe H, and Marynen P: The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21)associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999;93:3601-3609.
11. Sato Y, Akiyama Y, Tanizawa T, Shibata T, Saito K, Mori S, Kamiyama R, and Yuasa Y: Molecular characterization of the genomic breakpoint junction in the t(11;18) (q21;q21) translocation of a gastric MALT lymphoma. Biochem Biophys Res Commun 2001;280:301-306.
12. Ye H, Dogan A, Karran L, Willis TG, Chen L, Wlodarska I, Dyer MJ, Isaacson PG, and Du MQ: BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma. Am J Pathol 2000;157:1147-1154.
13. Cavalli F, Isaacson PG, Gascoyne RD, and Zucca E: MALT lymphomas. Hematology (Am Soc Hematol Educ Prog) 2001:241-258.
14. Streubel B, Vinatzer U, Lamprecht A, Raderer M, and Chott, A: T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005; 19:652-658.
15. Sanchez-Izquierdo D, Buchonnet G, Sieben R, Gascoyne RD, Climent J, Karran L, Marin M, Blesa D, Horsman D, Rosenwald A, Staudt LM, Albertson DG, Du MQ, Ye H, Marynen P, Garcia-Conde J, Pinkel D, Dyer MJ, and Martinez-Climent JA: MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood 2003;101:4539-4546.
16. Streubel B, Lamprecht A, Dierlamm J, Cerroni L, Stolte M, Ott G, Raderer M, and Chott A: T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003;101:2335-2339.
17. Uren AG, O'Rourke K, Aravind LA, Pisabarro MT, Seshagiri S, Koonin EV, and Dixit VM: Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell 2000;6:961-967.
18. Ruland J, Duncan GS, Wakeham A, and Mak TW: Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity 2003;19:749-758.
19. Thome M: CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. Nat Rev Immunol 2004;4:348-359.
20. Izumiyama K, Nakagawa M, Yonezumi M, Kasugai Y, Suzuki R, Suzuki H, Tsuzuki S, Hosokawa Y, Asaka M, and Seto M: Stability and subcellular localization of API2-MALT1 chimeric protein involved in t(11;18) (q21;q21) MALT lymphoma. Oncogene 2003;22:8085-8092.
21. Stoffel A, Chaurushiya M, Singh B, and Levine AJ: Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis. Proc Natl Acad Sci USA 2004;101:9079-9084.
22. Ruefli-Brasse AA, French DM, and Dixit VM: Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase. Science 2003;302:1581-1584.
23. Ho L, Davis RE, Conne B, Chappuis R, Berczy M, Mhawech P, Staudt LM, and Schwaller J: MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood 2005;105:2891-2899.
24. Hosokawa Y: Anti-apoptotic action of API2-MALT1 fusion protein involved in t(11;18)(q21;q21) MALT lymphoma. Apoptosis 2005;10:25-34.
25. Nakagawa M, Seto M, and Hosokawa Y: Molecular pathogenesis of MALT lymphoma: two signaling pathways underlying the antiapoptotic effect of API2-MALT1 fusion protein. Leukemia 2006;20:929-936.
26. Largo C, Alvarez S, Saez B, Blesa D, Martin-Subero JI, Gonzalez-Garcia I, Brieva JA, Dopazo J, Siebert R, Calasanz MJ, and Cigudosa JC: Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma. Haematologica 2006;91:184-191.
27. Akagi T, Motegi M, Tamura A, Suzuki R, Hosokawa Y, Suzuki H, Ota H, Nakamura S, Morishima Y, Taniwaki M, and Seto M: A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 1999;18:5785-5794.
28. Roncador G, Garcia JF, Garcia JF, Maestre L, Lucas E, Menarguez J, Ohshima K, Nakamura S, Banham AH, and Piris MA: FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia 2005;19:2247-2253.
29. Garcia JF, Roncador G, Garcia JF, Sanz AI, Maestre L, Lucas E, Montes-Moreno S, Fernandez Victoria R, Martinez-Torrecuadrara JL, Marafioti T, Mason DY, and Piris MA: PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. Haematologica 2006; 91:467-474.
30. Ye H, Gong L, Liu H, Hamoudi RA, Shirali S, Ho L, Chott A, Streubel B, Sieben R, Gesk S, Martin-Subero JI, Radford JA, Banerjee S, Nicholson AG, Ranaldi R, Remstein ED, Gao Z, Zheng J, Isaacson PG, Dogan A, and Du MQ: MALT lymphoma with t(14;18) (q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. J Pathol 2005;205:293-301.
31. Isaacson PG and Du M-Q: MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004;4:644-653.
32. Bertoni F and Zucca E: Delving deeper into MALT lymphoma biology. J Clin Invest 2006;116:22-26.